Literature DB >> 15528704

Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus.

Anne-Marie Roque-Afonso1, Liliane Grangeot-Keros, Bénédicte Roquebert, Delphine Desbois, Jean-Dominique Poveda, Vincent Mackiewicz, Elisabeth Dussaix.   

Abstract

Diagnosis of acute hepatitis A virus (HAV) infection is based on the detection of HAV immunoglobulin M (IgM). However, IgM could be detected due to nonspecific polyclonal activation of the immune system. An avidity test for anti-HAV IgG was developed to distinguish acute infection, where low-avidity antibodies are detected, from immune reactivation. The assay was tested on 104 samples, including 11 sera from patients with past infection, 15 sera from patients with acute infection and 4 collected after recovery, 10 sera from vaccinated subjects, 4 sera from patients with suspected immune reactivation, and 60 unselected HAV-IgM positive sera, collected over 1 year in a routine laboratory. The avidity index (AI) was expressed as percentage. The results were provided as the mean +/- one standard deviation. Patients with a history of prior infection had AIs of >70% (mean, 86% +/- 10), whereas the mean AI was 36% +/- 16 during acute HAV infection (P < 0.001). Within the first month after the onset of hepatitis, avidity was either noncalculable due to a very low IgG titer or <50%. In patients with immune reactivation, avidity was >70% (88% +/- 10%), a finding consistent with a prior infection. Among the 60 unselected sera, 35 (58%) had a noncalculable or <50% avidity, and most of them had a detectable HAV RNA, confirming HAV infection. In contrast, 16 (27%) had an avidity of >70%, and none was reverse transcription-PCR positive, suggesting immune reactivation. These 16 patients were significantly older than the others (50 +/- 16 years versus 26 +/- 14 years). The new anti-HAV IgG avidity assay we developed could improve HAV infection diagnosis, particularly in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528704      PMCID: PMC525178          DOI: 10.1128/JCM.42.11.5121-5124.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection in pregnant women.

Authors:  L Grangeot-Keros; M J Mayaux; P Lebon; F Freymuth; G Eugene; R Stricker; E Dussaix
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

2.  Maturation of IgG avidity to individual rubella virus structural proteins.

Authors:  J Nedeljkovic; T Jovanovic; C Oker-Blom
Journal:  J Clin Virol       Date:  2001-08       Impact factor: 3.168

3.  The changing epidemiology of hepatitis A in Italy.

Authors:  T Stroffolini; R D'Amelio; P M Matricardi; P Chionne; A Napoli; M Rapicetta; S Crateri; P Pasquini
Journal:  Ital J Gastroenterol       Date:  1993 Aug-Sep

4.  Duration of viremia in hepatitis A virus infection.

Authors:  W A Bower; O V Nainan; X Han; H S Margolis
Journal:  J Infect Dis       Date:  2000-06-27       Impact factor: 5.226

5.  Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity.

Authors:  M Söderlund; C S Brown; B J Cohen; K Hedman
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

6.  Viral and clinical factors associated with the fulminant course of hepatitis A infection.

Authors:  Guilhermo Rezende; Anne Marie Roque-Afonso; Didier Samuel; Michele Gigou; Elisabeth Nicand; Virginie Ferre; Elisabeth Dussaix; Henri Bismuth; Cyrille Féray
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

7.  A case of prolonged human parvovirus B19 DNA-emia associated with polyclonal B cell activation.

Authors:  T Nobutoki; H Hori; M Higashigawa; E Azuma; M Sakurai; T Yoshizumi; T Nunoue
Journal:  Acta Paediatr Jpn       Date:  1996-08

8.  Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox.

Authors:  A K Junker; P Tilley
Journal:  J Med Virol       Date:  1994-06       Impact factor: 2.327

9.  Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.

Authors:  S M Aalto; K Linnavuori; H Peltola; E Vuori; B Weissbrich; J Schubert; L Hedman; K Hedman
Journal:  J Med Virol       Date:  1998-11       Impact factor: 2.327

10.  [Seroprevalence of hepatitis A in hospitalized patients in Limoges University Hospital].

Authors:  François Denis; Christian Delpeyroux; Caroline Debrock; Sylvie Rogez; Sophie Alain
Journal:  Gastroenterol Clin Biol       Date:  2003 Aug-Sep
View more
  9 in total

1.  Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection.

Authors:  Harry E Prince; Mary Lapé-Nixon; Michael P Busch; Leslie H Tobler; Gregory A Foster; Susan L Stramer
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Primary and probable secondary dengue virus (DV) infection rates in relation to age among DV IgM-positive patients residing in the United States mainland versus the Caribbean islands.

Authors:  Harry E Prince; Cindy Yeh; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

3.  The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos.

Authors:  Bounkong Syhavong; Bouachanh Rasachack; Lee Smythe; Jean-Marc Rolain; Anne-Marie Roque-Afonso; Kemajittra Jenjaroen; Vimone Soukkhaserm; Simmaly Phongmany; Rattanaphone Phetsouvanh; Sune Soukkhaserm; Te Thammavong; Mayfong Mayxay; Stuart D Blacksell; Eleanor Barnes; Philippe Parola; Elisabeth Dussaix; Didier Raoult; Isla Humphreys; Paul Klenerman; Nicholas J White; Paul N Newton
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-04-07       Impact factor: 2.184

4.  Development of fully automated determination of marker-specific immunoglobulin G (IgG) avidity based on the avidity competition assay format: application for Abbott Architect cytomegalovirus and Toxo IgG Avidity assays.

Authors:  Ingo Curdt; Gerald Praast; Eva Sickinger; Jan Schultess; Iris Herold; Hans Bertram Braun; Stephanie Bernhardt; Gregory T Maine; Darwin D Smith; Stephen Hsu; Heike M Christ; Dominick Pucci; Michael Hausmann; Jörg Herzogenrath
Journal:  J Clin Microbiol       Date:  2009-01-07       Impact factor: 5.948

5.  Seroprevalence and Molecular Characterisation of Human Hepatitis A virus in Serum Samples of Tunisian Patients with Clinical Symptoms of Viral Hepatitis.

Authors:  Hakima Gharbi-Khelifi; Nabil Ben Salem Abid; Abir Beji; Leila Bhiri; Rafik Harrath; Khira Sdiri; Sylviane Billaudel; Virginie Ferre; Mahjoub Aouni
Journal:  Indian J Virol       Date:  2012-03-25

6.  Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins.

Authors:  Paola Di Bonito; Felicia Grasso; Stefania Mochi; Luisa Accardi; Maria Gabriella Donà; Margherita Branca; Silvano Costa; Luciano Mariani; Alberto Agarossi; Marco Ciotti; Kari Syrjänen; Colomba Giorgi
Journal:  Infect Agent Cancer       Date:  2006-11-08       Impact factor: 2.965

7.  Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens.

Authors:  Colomba Giorgi; Paola Di Bonito; Felicia Grasso; Stefania Mochi; Luisa Accardi; Maria Gabriella Donà; Margherita Branca; Silvano Costa; Luciano Mariani; Alberto Agarossi; Marco Ciotti; Kari Syrjänen
Journal:  Infect Agent Cancer       Date:  2008-06-26       Impact factor: 2.965

8.  Epidemiology of hepatitis A virus infections, Germany, 2007-2008.

Authors:  Mirko S Faber; Klaus Stark; Susanne C Behnke; Eckart Schreier; Christina Frank
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

Review 9.  The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity).

Authors:  Georg Bauer
Journal:  J Med Virol       Date:  2020-07-15       Impact factor: 20.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.